Incidence of active tuberculosis in HIV-infected individuals not receiving universal tuberculosis preventive treatment
Ling Chen,Lifan Zhang,Leidan Zhang,Liyuan Zheng,Jia Tang,Xiaojing Song,Yanling Li,Xiaoxia Li,Wei Lv,Ling Luo,Fuping Guo,Xinchao Liu,Guiren Ruan,Huanling Wang,Yang Han,Taisheng Li,Wei Cao
DOI: https://doi.org/10.1097/cm9.0000000000003394
IF: 6.133
2024-12-04
Chinese Medical Journal
Abstract:To the Editor : Tuberculosis (TB) is the leading cause of death in people living with HIV (PLWH) globally. Given the increased risk of TB infection, TB preventive therapy (TPT) is recommended for PLWH to prevent TB activation and to reduce relevant mortality. However, the implementation of TPT remains weak with only 21% of eligible PLWH initiated on TPT globally in 2021, [ 1 ] primarily due to the implementation challenges in developing countries. The low completion rate of TPT may be attributed to various reasons, including socio-economic factors, individual behaviors (medication adherence, lack of knowledge, etc.), unstable supply chain of anti-TB drugs, and insufficient understanding of TB treatment guidelines. China has always been regarded as a region with high TB burden. Therefore, conditional TB prophylaxis has been recommended in national guidelines for HIV-infected patients since 2006, with emphasis on those with CD4 + T count <200 cells/μL, or those with positive tests of latent TB screening, preferred using interferon γ release assay (IGRA). Since 2021, universal TB prophylaxis strategy has been recommended following the World Health Organization (WHO) guidelines. However, in real practice, HIV-infected individuals seldomly receive universal TPT when initiating antiretroviral therapy (ART) in most centers. Nevertheless, there is little report on the incidence of active TB development following ART initiation of HIV-infected individuals in China. In addition, whether a universal prophylaxis strategy would benefit the population also depends on the population-based prevalence of TB activation, as well as therapeutic cost and drug-related adverse events. Therefore, we here aim to compile the prevalence of active TB of PLWH in the first five years of initiating ART in one comprehensive referring center in Beijing China, providing real-world data for a more individualized TPT in HIV-infected individuals.
medicine, general & internal